Northwire Canada EditionWednesday, July 15, 2026
Northwire
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%
M&A / Property

Microbix adds CAP as QAP customer

MBX · Price

Executive Summary

  • Microbix Biosystems Inc. has secured the College of American Pathologists (CAP) as a client for the supply of Quality Assessment Products (QAPs) to support CAP’s clinical laboratory proficiency-testing (PT) and external quality assessment (EQA) programs.
  • The agreement follows a merit-driven selection process and involves the supply of multiple SKUs of Microbix QAPs, which emulate patient specimens to validate diagnostic test workflows.
  • Microbix aims to expand its product offerings and support multiple CAP PT/EQA programs throughout fiscal 2026 and beyond, leveraging its expertise in viral and bacterial QAPs for ISO 17043-certified programs.

Key Details

  • Client: The College of American Pathologists (CAP), a member-based organization of approximately 20,000 board-certified pathologists and a global leader in laboratory quality assurance.
  • Product Supply: Microbix is supplying Quality Assessment Products (QAPs) specifically for CAP’s PT/EQA programs.
  • Product Specifications: The QAPs are designed to fully emulate patient specimens while remaining safe and stable, validating workflows from specimen collection to final results.
  • Technical Expertise: Microbix utilizes expertise in the culture, purification, and inactivation of infectious disease pathogens, using well-characterized strains and synthetic biology to ensure accurate and consistent results.
  • Confidentiality: Specific CAP PT/EQA programs supported by Microbix remain confidential to maintain the blinding of participating clinical laboratories regarding the patient-sample mimetics used.
  • Future Outlook: Microbix intends to support multiple CAP PT/EQA programs and strengthen client relationships through fiscal 2026 and beyond.
  • Company Background: Microbix has over 120 skilled employees and reported revenues of $18.6 million in its latest fiscal year (2025). Its antigens drive antibody tests for approximately 100 diagnostics makers, and its QAPs/QUANTDx products are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs in over 30 countries.

Notable Quotes

  • "Microbix is pleased to welcome the College of American Pathologists as a client and is thankful for its support of our own efforts to improve laboratory-based medicine by creating the best possible quality assessment products to support globally important PT/EQA programs. We look forward to continuing to assist with CAP objectives and programs." — Cameron Groome, Chief Executive Officer and President of Microbix
Read the original news release →

More from Microbix Biosystems Inc